{"id":50631,"date":"2025-03-18T20:50:02","date_gmt":"2025-03-18T20:50:02","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=50631"},"modified":"2025-03-25T10:04:32","modified_gmt":"2025-03-25T10:04:32","slug":"tecovirimat-has-no-benefit-against-mpox-in-stomp-study","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/50631","title":{"rendered":"CROI 2025: Tecovirimat has no benefit against mpox in STOMP study"},"content":{"rendered":"

Simon Collins, HIV i-Base<\/strong><\/p>\n

Last year two randomised controlled studies were stopped early for futility after showing no benefit as a treatment against mpox, but only limited details were released by press release.<\/strong><\/p>\n

Several months later, details of the NIH PALM007 study conducted at two sites in the DRC were presented at IDWeek and were reported in HTB. [1]<\/p>\n

Full results from the US-based international STOMP study were presented at CROI 2025.<\/p>\n

STOMP randomised 344 participants with confirmed mpox clade 2 (2:1) to a 14-day course of tecovirimat or placebo. Nearly all were cisgender men (3% transgender), with one-third living with HIV and one-third with severe pain. Median number of lesions was 8 (range: 4 to 18).<\/p>\n

There were no differences in clinical resolution at day 29: 83% vs 84%, p=0.89, or mean (SD) pain score reduction (3.2 [2.1] vs 3.1 [2.0]), both in the active vs placebo groups respectively.<\/p>\n

There were also no differences in various subpopulation analyses including early treatment and severity of pain.<\/p>\n

Although further analyses are still ongoing, the presentation concluded with the urgency of finding effective treatments for mpox.<\/p>\n

References<\/p>\n

    \n
  1. HTB. Detailed results from PALM007 study: no clinical impact of tecovirimat against mpox clade 1. HTB (January 2025).
    \ni-base.info\/htb\/50006<\/a><\/li>\n
  2. Wilkin T et al for the ACTG A5418 Study Team. Tecovirimat Is Safe but Not Efficacious in People With Clade II Mpox. CROI 2025. Oral abstract 200.
    \n<\/span>    www.croiconference.org\/abstract\/3822-2025<\/a> (abstract)
    \n<\/span>    watch.croiwebcasts.org\/2025croi\/ap\/54367<\/a> (webcast for delegates)<\/span><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Simon Collins, HIV i-Base Last year two randomised controlled studies were stopped early for futility after showing no benefit as a treatment against mpox, but only limited details were released by press release. Several months later, details of the NIH …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,323],"tags":[339],"class_list":["post-50631","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-mpox","tag-croi-2025"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/50631","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=50631"}],"version-history":[{"count":10,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/50631\/revisions"}],"predecessor-version":[{"id":50740,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/50631\/revisions\/50740"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=50631"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=50631"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=50631"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}